| Autor: |
Tachet, J., Dumusc, A., Conrad, C., Grandoni, F., Chalandon, Y., Ribi, C., Buclin, T., Girardin, F. |
| Jazyk: |
francouzština |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Revue medicale suisse, vol. 18, no. 800, pp. 1979-1983 |
| Popis: |
Janus kinase inhibitors (JAKi), such as tofacitinib, baricitinib, upadacitinib or ruxolitinib, are small molecules active on specific intracellular targets and used orally for the treatment of autoimmune or myeloproliferative diseases. Their remarkable therapeutic efficacy is offset by a significant risk of toxicities, essentially dose-dependent and a variable pharmacokinetic profile. The JAKi represent a new therapeutic armamentarium for treating autoimmune, myeloproliferative and inflammatory diseases (incl. COVID-19), but require thorough treatment individualization and close monitoring. Therapeutic Drug Monitoring (TDM) of JAKi could allow a personalized prescription and improve the efficacy-toxicity profile. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
